TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Safety, Efficacy and Tolerability of Vilazodone in Patients With Generalized Anxiety Disorder

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male and female, 18 - 70 Years of age~* Currently meet the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR) criteria for Generalized Anxiety Disorder (GAD)~* Minimum score of 20 on the Hamilton Rating Scale for Anxiety (HAM-A)~Exclusion Criteria:~* Women who are pregnant, women who will be breastfeeding during the study, and women of childbearing potential who are not practicing a reliable method of birth control~* Patients with a history of meeting DSM-IV-TR criteria for:~  * any manic, hypomanic or mixed episode, including bipolar disorder and substance-induced manic, hypomanic, or mixed episode;~ * any depressive episode with psychotic or catatonic features;~ * panic disorder with or without agoraphobia;~ * obsessive-compulsive disorder;~ * Schizophrenia, schizoaffective, or other psychotic disorder;~ * bulimia or anorexia nervosa;~ * presence of borderline personality disorder or antisocial personality disorder;~ * mental retardation, dementia, amnesia, or other cognitive disorders~* Patients who are considered a suicide risk

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Matching placebo tablets, oral administration
- Vilazadone (Type: EXPERIMENTAL): Vilazadone tablets, oral administration

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: E-health Care Process Support for Diabetes Type II Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Type 2 diabetes, treated with non-pharmacological interventions or/and tablets (Non-Insulin-Dependent Diabetes Mellitus)~* Internet connection and personal computer /lap-top computer~* Mobile phone~* Sufficient level of Internet and e-mail usage - checked by short questionnaire~* Age \>18 or \<75 years~Exclusion Criteria:~* significant co-morbidity~* Type 1 diabetes~* Insulin-dependent type 2 diabetes

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Diabetes with ICT support (E-diabetes) (Type: EXPERIMENTAL): The group of randomly selected patients with DM type II, who will get the software application and web- based support Intervention: Computerised support to the Diabetes type II patients
- Diabetes without support (Type: NO_INTERVENTION): The group of randomly selected patients with DM type II, without software application and web-based support.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Portion Size Over 5 Days in Preschool Children

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Attending one of the designated childcare centers~Exclusion Criteria:~* Food Allergies~* Food Restrictions~* Health Issues that Preclude Participation~* Not available for duration of the study

- Gender: ALL
- Minimum Age: 3 Years
- Maximum Age: 5 Years
- Healthy Volunteers: f

Study Arms:
- 100% Portion Size (Type: EXPERIMENTAL): 100% Food and Beverage Portion Size
- 150% Portion Size (Type: EXPERIMENTAL): 150% Food and Beverage Portion Size

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Oseltamivir (Tamiflu) for Treatment of Influenza in Immunocompromised Participants.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Rapid diagnostic test, PCR, or viral culture positive for influenza in the 96 hours prior to first dose~* Immunocompromised participants with primary or secondary immunodeficiency~* Symptoms suggestive of influenza-like illness~* Use of an effective contraceptive, as specified by protocol; women of childbearing potential cannot be pregnant or breastfeeding~Exclusion Criteria:~* Influenza vaccination with live attenuated vaccine in the 2 weeks prior to randomization~* Antiviral treatment for influenza in 2 weeks prior to randomization~* Severe hepatic impairment~* Any current renal replacement therapy~* Any gastrointestinal disorders which may interfere with the absorption of oseltamivir~* Participation in a study with an investigational drug from 4 weeks prior to study start until study end

- Gender: ALL
- Minimum Age: 1 Year
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Conventional dose (Type: EXPERIMENTAL): Immunocompromised participants will receive oseltamivir syrup at a dose ranging from 30 to 75 mg based on body weight, twice daily for children (1 to 12 years old) and oseltamivir capsules 75 mg twice daily for adults/adolescents greater than or equal to (\>/=) 13 years old or placebo-matched to oseltamivir twice daily over 10 days.
- Double dose (Type: EXPERIMENTAL): Immunocompromised participants will receive oseltamivir syrup at a dose ranging from 60 to 150 mg based on body weight, twice daily for children (1 to 12 years old) and oseltamivir capsules 150 mg twice daily for adults/adolescents (\>/=13 years old) or placebo matched to oseltamivir twice daily over 10 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of Talazoparib, a PARP Inhibitor, in Patients With Advanced or Recurrent Solid Tumors

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically or cytologically documented, unresectable, locally advanced or metastatic solid tumor~* Must have available archived tumor tissue (formalin-fixed paraffin-embedded) \[FFPE\].~* 18 years of age or older.~* Have measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST, v1.1) or increased CA-125 (ovarian cancer) or PSA (prostate cancer) and/or CA 19-9 (pancreatic cancer).~* Eastern Cooperative Oncology Group (ECOG) performance status ≤ 1.~* Have adequate organ function~* Able to take oral medications.~* Willing and able to provide informed consent.~* Sexually active patients must be willing to use an acceptable method of contraception.~* Females of childbearing potential must have a negative serum pregnancy test at screening.~* Willing and able to comply with all study procedures.~Part 2 Dose Expansion Tumor Types:~* Breast and ovarian cancer patients with deleterious or pathogenic BRCA mutations who have received no more than 4 prior regimens for metastatic disease.~* Prostate or pancreatic cancer patients with deleterious or pathogenic BRCA mutations who have received no more than 2 prior regimens for metastatic disease.~* Small cell lung cancer (SCLC) patients who have received no more than one prior regimen for SCLC.~* Ewing's sarcoma patients who have received no more than 3 prior regimens for metastatic disease.~Exclusion Criteria:~* Part 2 Expansion: Prior treatment with a PARP inhibitor.~* Has history of central nervous system (CNS) metastasis.~  \* Exception: In patients with SCLC, history of adequately treated brain metastasis who do not require corticosteroids for management of CNS symptoms.~* Has had major surgery within 28 days before Cycle 1, Day 1.~* Has active peptic ulcer disease.~* Active gastrointestinal tract disease with malabsorption syndrome.~* Pregnant or breastfeeding at screening or planning to become pregnant (in each case, either oneself or one's partner) at any time during the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Talazoparib (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Periodontal Infection and Endothelial Dysfunction

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects must be 25 years of age or older~* Three or more periodontal pockets with a probing depth (PD) \> 5mm~* Have at least 20 natural teeth~* Provide informed consent and willingness to cooperate with the study protocol~Exclusion Criteria:~* History of antibiotic use in the previous three months~* Pregnant or lactating females~* Treatment with antihypertensive, antilipemic, antiarrhythmic, and other cardiovascular drugs~* Systemic diseases such as diabetes, HIV/AIDS, liver disease, chronic renal failure, tuberculosis, and autoimmune diseases~* Previous history of cardiovascular disease: Acute myocardial infarct, stable angina, unstable angina, heart failure, atrial fibrillation, atrioventricular block, peripheral vascular disease, cerebrovascular accident~* Patients who received periodontal treatment within the last 3 months~* Patients who require antibiotic prophylaxis before examination or treatment~* Patients with mental retardation and dementia

- Gender: ALL
- Minimum Age: 25 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- One-Stage Full-Mouth Disinfection (Type: EXPERIMENTAL): Scaling and root planing, four quadrants in one session Tongue brushing with a 1% chlorhexidine gel (1 minute) Mouth rinsing with a 0.2% chlorhexidine solution for (2 minutes) Subgingival chlorhexidine (1%) irrigation in all pockets Twice daily rinsing with clorhexidine (1 minute) during fourteen days after the periodontal intervention Basic oral hygiene instructions Dental extractions will be performed at the end of patient followup (only in cases of teeth that could not be saved)
- Periodontal care (Type: ACTIVE_COMPARATOR): Basic oral hygiene instructions Supragingival plaque removal

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Persistent Pain After CS Delivery

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: OTHER
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* \>/= 18 years of age English speaking~Exclusion Criteria:~non-English speaking

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Study Arms:
- cesarean section deliveries (Type: None): those subjects having an elective cesarean section will complete an informed consent form, complete the preoperative questionnaire, and then be contacted for 60 days postoperatively

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Establish the Efficacy of QBX258 in Patients With Moderate to Severe Asthma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with atopic asthma \>1 year duration diagnosed according to the GINA guidelines.~* Subjects must weigh at least 50 kg to participate in the study, and must have a body mass index (BMI) within the range of 18 - 39 kg/m2.~* Asthma which is not adequately controlled on current treatment, as demonstrated by an Asthma Control Questionnaire (ACQ) score of \> 1.5.~* FEV1 40 to 90% of predicted.~Exclusion Criteria:~* Diagnosed with COPD as defined by the GOLD guidelines~* Subjects who have had a respiratory tract infection within 4 weeks prior to screening.~* Women of child-bearing potential must use highly effective methods of contraception during dosing and for at least 18 weeks after last study drug administration

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- QBX258 (Type: EXPERIMENTAL): Participants received QBX258 intravenous (iv) infusion every 4 weeks for up to 4 doses total.
- Placebo (Type: PLACEBO_COMPARATOR): Participants received placebo to QBX258 iv infusion every 4 weeks for up to 4 doses total.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Clinical Trial Comparing C-Brace to Knee Ankle Foot Orthosis (KAFO)/Stance Control Orthosis (SCO)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patient has been tested with the Trial Tool (DTO) and demonstrated the potential to utilize the C-Brace successfully~* Patient has a BBS score \< 45~* Lower limb functional impairment according to CE label wording~* Prior active and compliant use of unilateral or bilateral KAFO or SCO in the past 3 months prior to enrollment in the study~* Patient meets minimum physical requirements to be fitted with a C-Brace, such as muscle status, joint mobility, leg axis and proper control of the orthosis must be guaranteed.~* The User must fulfill the physical and mental requirements for perceiving optical/acoustic signals and/or mechanical vibrations~* The existing muscle strength of the hip extensors and flexors must permit the controlled swing-through of the limb (compensation using the hip is possible).~* Patient´s commitment to use C-Brace 2 at least 1-2 hours per day 5 days per week-~* Patient is ≥ 18 years old~* Patient is willing and able to independently provide informed consent.~* Person is willing to comply with study procedures~Exclusion Criteria:~* Patient who is not able to follow the entire study visits or is unwilling/unable to follow the instructions~* Patient was not able to use DTO~* Patient who is not using an orthosis at least 1 to 2 hours/ day for 5 days per week~* Patient with body weight \> 125 kg (includes body weight and heaviest object (weight) carried)~* Patient with Orthoprosthesis~* Patient with flexion contracture in the knee and/or hip joint in excess of 10°~* Patient with uncontrolled moderate to severe spasticity (relative contraindication moderate spasticity)~* Leg length discrepancy in excess of 15 cm~* Patient with unstable neurological or cardiovascular/pulmonary disease, cancer~* Pregnancy~* Patient using a C-Brace~* Patient with known vertigo or with history of falls unrelated to orthosis use or unrelated to motor disability~* Patient who has never been fitted an orthosis before~* Patient is not able to answer the self-administered questionnaires independently; for patients with upper extremity impairment is it allowed to verbally answer the questions.~* Patient participating already in a study during this study´s duration~* Patient participated in earlier C-Brace studies

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- KAFO/SCO (Type: ACTIVE_COMPARATOR): Home use of 3 months with existing knee ankle foot orthosis (KAFO) or existing stance control orthosis (SCO)
- C-Brace (Type: EXPERIMENTAL): Home use of 3 months with newly fitted C-Brace microprocessor-controlled stance and swing control orthosis.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Pharmacokinetics of Daptomycin During Cardiopulmonary Bypass Surgery

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Hospitalized patients, awaiting scheduled elective coronary artery bypass graft (CABG) surgery without valve replacement surgery~* Age \> 18 years and \< 75 years~* BMI between 18.5 and 35.0 kg/meters-squared~* Crcl \> 50 ml/minute calculated based on Cockcroft Gault equation~* No known active or suspected infection(s)~* Ability to complete the informed consent process~* Negative pregnancy test (for women of childbearing age)~Exclusion Criteria:~* History of allergic reaction to daptomycin or components of daptomycin~* Receipt of daptomycin within 7 days prior to the surgery~* Elevated CPK levels (defined as \> 3 times the upper limits of known normal)~* History of myopathy or complaints consistent with myopathy~* Current or planned use of mycophenolate mofetil, mycophenolic acid, or tobramycin during the subjects' current hospitalization (all of which are known to interact with daptomycin)~* Inability to complete the informed consent process because of problems with mental capacity~* Pregnancy and/or breast feeding

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: 74 Years
- Healthy Volunteers: f

Study Arms:
- Cases (Type: EXPERIMENTAL): The first 15 subjects enrolled will receive the intervention drug daptomycin as surgical antibiotic prophylaxis.
- Controls (Type: NO_INTERVENTION): 15 subjects will be enrolled in the standard of care antibiotic group to serve as the controls. Controls will receive no experimental medications or treatments. The purpose of enrolling control patients was to serve as a reference group for intervention patients. Specifically cases and controls will be compared for changes in commonly collected hematologic parameters, creatinine, and CPK. Additionally, parameters collected during anesthesia will be compared. Controls will be matched to the intervention group by age (+/- 10 years), gender, and ethnicity.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate P-Glucose, Safety and Tolerability After Oral Single Dosing of AZD6370 in Type 2 Diabetic Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE1
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Treated with diet or metformin. Stable glycemic control indicated by no changed treatment within 3 months~* Diabetes Mellitus diagnosis \<5 years~Exclusion Criteria:~* Clinically significant illness or clinically relevant trauma, as judged by the investigator, within two weeks before the first administration of the investigational product~* Clinically significant abnormalities in clinical chemistry, hematology, or urinalysis results

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Part A, arm 1 (Type: EXPERIMENTAL): 1) 8 pats: AZD6370 increasing oral single doses a+b+c+placebo together with food
- Part A, arm 2 (Type: EXPERIMENTAL): 1) 8 pats: AZD6370 increasing oral single doses a+b+c+placebo without food
- Part B, arm1, 2, and 3 (Type: EXPERIMENTAL): 1. AZD6370 dose x mg o.d.~2. dose x/2 mg b.i.d.~3. dose x/4 mg q.i.d.
- Part B, arm 4 (Type: EXPERIMENTAL): 4) Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Trial of Lithium Carbonate for Treatment of Osteoporosis-pseudoglioma Syndrome

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Eligibility Criteria~Inclusion Criteria~* Age 4 years or greater~* Diagnosed with osteoporosis pseudoglioma syndrome (OPPG) or a first degree relative of someone with OPPG. For diagnosis of OPPG, one of the following is required: (1) congenital blindness in a child born into a family with known OPPG where at least one affected family member has had an LRP5 mutation demonstrated or (2) a child with no known family members with OPPG who has congenital blindness, DXA Z-score \< -2.0 and mutation in LRP5 documented~* No contraindications to lithium carbonate~* For women of child bearing age, willing to undergo urine pregnancy test~Exclusion Criteria~* Age under 4 years~* Not diagnosed with osteoporosis pseudoglioma (OPPG) syndrome or a first degree relative of someone with OPPG, or a member of the Old Order Mennonite community~* Pregnant~* For women of childbearing age, not willing to undergo urine pregnancy test~* Contraindication to Lithium (serum creatinine \> 1.3, known cardiovascular disease \[history of myocardial infarction, heart failure\], currently on diuretic or ACE inhibitor)~* Glomerular filtration rate below 80 cc/min

- Gender: ALL
- Minimum Age: 4 Years
- Maximum Age: 64 Years
- Healthy Volunteers: t

Study Arms:
- Lithium (Type: EXPERIMENTAL): patients with OPPG will be treated with lithium for 6 months
- Unaffected controls (Type: NO_INTERVENTION): Family members of patients with OPPG will have DXA and pQCT to compare to OPPG patients. These unaffected participants will not receive lithium.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effects of Lubiprostone on Gastric Function in Patients With Chronic Idiopathic Constipation

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* chronic idiopathic constipation~Exclusion Criteria:~* medications that slow gastrointestinal (GI) motility~* prior surgery to the GI tract

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Treatment (Type: EXPERIMENTAL): 24 micrograms of lubiprostone twice daily for one week.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete